Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma

Summary

At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. When contacted by a treating physician, BMS will consider requests for providing early patient access to Elotuzumab in patients with multiple myeloma who are residents of Belgium, Thailand, Turkey, Argentina, and Colombia.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications